✦ LIBER ✦

Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer

✍ Scribed by Khalid El Ouagari; Jon Karnon; Thomas Delea; Willena Talbot; Jane Brandman

Publisher: Springer US
Year: 2006
Tongue: English
Weight: 254 KB
Volume: 101
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-006-9262-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost utility analysis of early adjuvant

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

✍ Jonathan Karnon; Thomas Delea; Vicki Barghout 📂 Article 📅 2007 🏛 Springer 🌐 French ⚖ 297 KB

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

Extending the benefits of adjuvant thera

Extending the benefits of adjuvant therapy in early HR+ breast cancer

✍ Paul E. Goss 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 213 KB

Assessing the cost effectiveness of adju

Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model

✍ Bruce E. Hillner; Thomas J. Smith; Christopher E. Desch 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 697 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the